Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Figure 2 2 Data of efficacy 2.1 Clinical trials: the SURPASS program The central clinical trial program designed to demonstrate the therapeutic effectiveness (in terms of GC and BW reduction), tolerability and safety of TZP in diabetic patients was the SURPASS program
Moreover, mechanistic readouts and clinical endpoints are rarely integrated
Side effects often temporarily worsened when the dose was uptitrated
Nygrd O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, and Vollset SE (1997a)
US$ 20.33
US$ 27.28
US$ 27.19
US$ 25.15
US$ 28.06
